Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 881 across all filing types
Latest filing 2020-12-22 Regulatory Filings
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
AVE begins Human Trial on CBD product 2 pages 193.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 23 December 2020 from Avecho Biotechnology Limited. It discusses the company's initiation of participation in an observational study testing an enhanced cannabidiol formulation. The content focuses on clinical trial participation, product development updates, and regulatory context (TGA down-scheduling of CBD). There are no financial statements, detailed financial performance data, or comprehensive management analysis. The document is a corporate announcement about a clinical study and product development progress rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a call transcript, board change, or capital update. The document is a general regulatory announcement about company activities and clinical trial participation, which fits best under Regulatory Filings (RNS). The document length (7866 characters) and content confirm it is not a brief report publication announcement or a certification. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-12-22 English
Grant of Unlisted Options & Appendix 3G 13 pages 418.1KB
Share Issue/Capital Change Classification · 100% confidence The document is an ASX announcement dated 20 November 2020 regarding the grant of unlisted options to executives, staff, and directors of Avecho Biotechnology Limited. It includes an Appendix 3G, which is a notification form for the issue of equity securities under an employee incentive scheme. The content focuses on the issuance of unlisted options, details of recipients, and compliance with ASX listing rules. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory announcement about capital changes related to employee incentives and share options. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is substantial (15,000 characters), and it is not merely an announcement of a report but the actual notification of securities issuance.
2020-11-19 English
Improved Propofol TPM Formulation Passes Toxicology Study 2 pages 70.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 4 November 2020 from Avecho Biotechnology Limited. It discusses the successful completion of a toxicology study for an improved Propofol TPM formulation, highlighting the safety results and ongoing licensing discussions. The content is a corporate update on a product development milestone rather than a financial report, regulatory filing, or management discussion. It does not contain financial statements, earnings data, or detailed management analysis. It is also not a notice of voting results, board changes, or legal proceedings. The document is a typical market announcement informing investors and the market about a significant product development event. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2020-11-03 English
September 2020 Quarterly Activities Report & Appendix 4C 7 pages 337.7KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 28 October 2020, titled 'Avecho Quarterly Activities Report and Appendix 4C' for the quarter ended 30 September 2020. It contains detailed operational updates, financial highlights including cash flow statements, and an Appendix 4C which is a quarterly cash flow report required by ASX Listing Rule 4.7B. The content includes substantive financial data and analysis for a quarter, not just a brief announcement or a link to a report. This matches the definition of an Interim / Quarterly Report (IR). It is not a full annual report, nor a simple announcement or certification. Therefore, the correct classification is IR with high confidence. Q1 2021
2020-10-27 English
Response to ASX Price Query 3 pages 804.2KB
Regulatory Filings Classification · 95% confidence The document is a correspondence between ASX Compliance and Avecho Biotechnology Limited regarding a price query about the company's securities. It includes a request for information from ASX about unusual trading activity and the company's response confirming compliance with listing rules and absence of undisclosed information. There are no financial statements, management discussion, or report content. The document is a regulatory communication related to compliance and disclosure obligations rather than a financial report or announcement of results. It fits best under Regulatory Filings (RNS) as it is a compliance-related letter and response to a regulatory inquiry.
2020-10-25 English
TPM Cannabinoid Development Program Update 2 pages 118.3KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Avecho Biotechnology Limited regarding the progress of their cannabinoid development program to human clinical trials. It contains highlights of in vivo study results, details about the development program phases, and market opportunity information. There are no financial statements, regulatory certifications, or detailed financial data presented. The document is an update on a specific project and its progress rather than a formal financial report or regulatory filing. It is also not a report publication announcement since it contains substantive information about the program's progress and study results. The content fits best as a general regulatory announcement or market update. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-10-18 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.